Companies ›Basic Materials ›352940.KQ

352940.KQ — KOSDAQ Agricultural Chemicals

EnBio Co Ltd

$2 055,00

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

21,4 %

ROE

6,3 %

Net margin

17,5 %

Debt / equity

0,40

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

EnBio Co Ltd maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.4, indicating a moderate reliance on debt financing. However, the company's liquidity position is concerning, as it holds negative cash and equivalents of KRW -1,091,867,990 and has a negative operating cash flow of KRW -2,699,363,470. This suggests potential short-term liquidity constraints, especially given the negative free cash flow of KRW -2,488,697,320. Profitability metrics show a return on equity (ROE) of 6.28% and a return on assets (ROA) of 3.7%, which are below the industry median for Agricultural Chemicals. The company's operating income of KRW 3,346,116,270 and net income of KRW 2,729,466,170 indicate a profitable operation, but the gross profit margin of 42.36% (KRW 6,613,319,160 on KRW 15,610,903,220 revenue) suggests room for improvement in cost control. Geographically and segment-wise, EnBio's revenue concentration is not disclosed in the available data. However, the company's exposure to the agricultural chemicals market is significant, and its performance is likely influenced by global demand for agrochemicals and regulatory changes in key markets. Looking ahea

Business. EnBio Co Ltd (352940.KQ) is a South Korean company listed on the KOSDAQ that operates within the agricultural chemicals industry. The firm is engaged in the production and sale of chemical products, primarily serving the agricultural sector. Specific details regarding its operating segments and geographic revenue mix are not available. The company is headquartered in South Korea.

Classification92 %

SectorBasic Materials

Business sectorChemicals

IndustryAgricultural Chemicals

ActivityChemicals

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

6,3 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 352940.

Sector rotation

Sector1D1Mvs mkt

Materials · THIS SECTOR+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 352940.KQ. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

EnBio Co Ltd (352940.KQ) is a South Korean company listed on the KOSDAQ that operates within the agricultural chemicals industry. The firm is engaged in the production and sale of chemical products, primarily serving the agricultural sector. Specific details regarding its operating segments and geographic revenue mix are not available. The company is headquartered in South Korea.

Classification92 %

SectorBasic Materials

Business sectorChemicals

IndustryAgricultural Chemicals

ActivityChemicals

AI synthesis

GENERATED

Profitability metrics show a return on equity (ROE) of 6.28% and a return on assets (ROA) of 3.7%, which are below the industry median for Agricultural Chemicals. The company's operating income of KRW 3,346,116,270 and net income of KRW 2,729,466,170 indicate a profitable operation, but the gross profit margin of 42.36% (KRW 6,613,319,160 on KRW 15,610,903,220 revenue) suggests room for improvement in cost control.

Geographically and segment-wise, EnBio's revenue concentration is not disclosed in the available data. However, the company's exposure to the agricultural chemicals market is significant, and its performance is likely influenced by global demand for agrochemicals and regulatory changes in key markets.

Looking ahead, EnBio's growth trajectory is uncertain. The company reported revenue of KRW 15,610,903,220 in the latest period, but no forward-looking revenue guidance is provided. The capital expenditure of KRW -6,258,872,740 indicates a significant investment in infrastructure or expansion, which could support future growth but may also strain liquidity in the short term.

Risk factors include the company's negative net cash position and the potential for liquidity constraints. The risk assessment indicates a medium liquidity risk and a low dilution risk, with no immediate pressure for equity issuance. However, the negative operating and free cash flows suggest the company may need to secure additional financing in the near term.

Recent events, including filings and transcripts, are not detailed in the available data. However, the company's financial performance and capital structure suggest a need for close monitoring of its liquidity and debt management strategies.

Key takeaways

EnBio maintains a conservative debt-to-equity ratio of 0.4 but faces liquidity challenges due to negative cash and equivalents.
The company's ROE of 6.28% and ROA of 3.7% are below industry medians, indicating room for improvement in profitability.
EnBio's capital expenditure of KRW -6,258,872,740 suggests a focus on long-term growth, but this may strain short-term liquidity.
The company's negative operating and free cash flows highlight the need for improved cash flow management.
EnBio's exposure to the agricultural chemicals market and regulatory changes in key markets could impact its future performance.

Bull / Bear case

Generated · model-assisted

BULL CASE · 2

Net income surged 56% year-over-year to 1.0 billion KRW, demonstrating strong recent profitability recovery.

The debt-to-equity ratio of 0.4 is below the 0.34 cohort median, indicating a conservative leverage position.

BEAR CASE · 4

Cash conversion of -0.99 places EnBio in the bottom quartile versus the 0.9 cohort median.

The company faces a high credit risk flag, signaling potential difficulties in meeting financial obligations.

Revenue declined 4.8% year-over-year to 34.0 billion KRW, indicating a contraction in top-line sales.

Free cash flow remains negative at -4.4 billion KRW, highlighting ongoing cash burn despite profitability.

In focus — financials by report

Valuation FY

Market price

$2 055,00

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$43.46B

Net cashⓘ

-$18.47B

Current ratioⓘ

1.9

Debt / equityⓘ

0.4

ROAⓘ

3.7%

ROEⓘ

6.3%

Cash conversionⓘ

-99.0%

CapEx / revenueⓘ

-40.1%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin21,4 %Best in class

Net Margin17,5 %Best in class

ROE6,3 %Above median

Capex / Rev-40,1 %Bottom quartile

D/E0,40Below median

Cash Conv-0,99Bottom quartile

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

EnBio Co Ltd Market data — financials · 2026-05-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

352940.KQCanonical

KOSDAQ · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread